Parameter
| Biomarker | PLT/PDW, PLR | Full name | Platelet count/Platelet distribution width ratio, Platelet-to-lymphocyte ratio | Molecular Type | Hematological parameters (cell ratios) |
|---|---|---|---|---|---|
| Molecular Formula | / | Molecular Weight | / | Core Functional Dimensions | Prognosis assessment (advanced cHL) |
| Disease | Non-Hodgkin Lymphoma (NHL) | Disease Subtypes | / | ||
| Organ | Blood and lymphoid tissue | Test Sample / Technology Platform | Whole blood (complete blood count) | ||
| Pathobiological Mechanisms | Reflects inflammatory status and immune dysregulation, with low PLT/PDW and high PLR indicating immunosuppression and elevated risk of tumor progression. | ||||
| Clinical Availability Status | Clinical validation phase: Multivariate analysis revealed that PLT/PDW <24.5 and PLR ≥245 were independent risk factors for adverse FFP and PFS. | ||||
| Notes and Dynamics | In early-stage chronic lymphocytic leukemia (cHL), platelet-rich blood (PLR) is also a reliable prognostic indicator and can be incorporated into routine complete blood count (CBC) risk assessment. | ||||